Compare CVS Health Corp (CVS) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs D R Horton Inc — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while D R Horton Inc trades at $150.79 (market cap $41.02B). The key difference: CVS Health Corp is far larger — about 3× D R Horton Inc's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | DHI | |
|---|---|---|
Market Cap | $122.36B | $41.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $184.04 |
52-Week Low | $65.51 | $132.53 |
Enterprise Value | $184.71B | $46.13B |
Dividend Yield | 2.78% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
D.R. Horton (DHI) trades at $151.08, up 3.47% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance amid persistent affordability pressures. Valuation metrics appear reasonable with a P/E of 14.4 and P/S of 1.32, while profitability remains solid with a net income margin of 9.15%.
The outlook is mixed: strong execution and cash returns provide support, but weaker demand and margin pressure pose headwinds. Investment opportunity lies in disciplined inventory management and shareholder returns, while risks include elevated mortgage rates and competitive threats from disruptors like Boxabl. Analyst sentiment is balanced with 45% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
